Related references
Note: Only part of the references are listed.PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer
Neda Yaghoubi et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Derin B. Keskin et al.
NATURE (2019)
Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143
Antonio Omuro et al.
NEURO-ONCOLOGY (2018)
Checkpoint inhibitors as treatment for malignant gliomas: A long way to the top
Matteo Simonelli et al.
CANCER TREATMENT REVIEWS (2018)
IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma
Erik Ladomersky et al.
CLINICAL CANCER RESEARCH (2018)
Immunotherapy of Primary Brain Tumors: Facts and Hopes
Robin A. Buerki et al.
CLINICAL CANCER RESEARCH (2018)
Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study
Margaret K. Callahan et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
The perfect personalized cancer therapy: cancer vaccines against neoantigens
Luigi Aurisicchio et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
Immune checkpoint therapy in liver cancer
Feng Xu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Joy Hsu et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Nobel committee honors tumor immunologists
Anand Rotte et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
Cancer immunologists scoop medicine Nobel prize
Heidi Ledford et al.
NATURE (2018)
Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy
A. Rotte et al.
ANNALS OF ONCOLOGY (2018)
Combination therapy to checkmate Glioblastoma: clinical challenges and advances
Debarati Ghosh et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2018)
Radiotherapy combination opportunities leveraging immunity for the next oncology practice
Fernanda G. Herrera et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas
Jennifer E. Kim et al.
CLINICAL CANCER RESEARCH (2017)
Epidemiology for primary brain tumors: a nationwide population-based study
Amelie Darlix et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomase
Gary Kohanbash et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Alexander C. Huang et al.
NATURE (2017)
Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent
Alice O. Kamphorst et al.
SCIENCE (2017)
Recurrent glioma clinical trial, CheckMate-143: the game is not over yet
Anna C. Filley et al.
ONCOTARGET (2017)
Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis
Rajeev K. Shrimali et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression
Julian P. Layer et al.
ONCOIMMUNOLOGY (2017)
Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples
Guanzhang Li et al.
ONCOIMMUNOLOGY (2017)
Polymeric nanoparticles promote macrophage reversal from M2 to M1 phenotypes in the tumor microenvironment
Yi Wang et al.
BIOMATERIALS (2017)
Discovery of IDO1 Inhibitors: From Bench to Bedside
George C. Prendergast et al.
CANCER RESEARCH (2017)
Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40
David J. Messenheimer et al.
CLINICAL CANCER RESEARCH (2017)
Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors
Anthony W. Tolcher et al.
CLINICAL CANCER RESEARCH (2017)
Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer
Clemence Granier et al.
ESMO OPEN (2017)
Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade
Dipongkor Saha et al.
CANCER CELL (2017)
Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment
Qianghu Wang et al.
CANCER CELL (2017)
The Kynurenine Pathway: A Primary Resistance Mechanism in Patients with Glioblastoma
Peter P. Sordillo et al.
ANTICANCER RESEARCH (2017)
PD-L1 Expression and Combined Status of PD-L1/PD-1-Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients
Jiheun Han et al.
JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE (2017)
PD-L1 expression and prognostic impact in glioblastoma
Edjah K. Nduom et al.
NEURO-ONCOLOGY (2016)
Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model
David A. Reardon et al.
CANCER IMMUNOLOGY RESEARCH (2016)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
Lymphocyte-activation gene-3, an important immune checkpoint in cancer
Yayi He et al.
CANCER SCIENCE (2016)
Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
Eric Bouffet et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors
Deborah T. Blumenthal et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
Bioinformatic profiling identifies an immune-related risk signature for glioblastoma
Wen Cheng et al.
NEUROLOGY (2016)
Expression of the galectin-9-Tim-3 pathway in glioma tissues is associated with the clinical manifestations of glioma
Zengjin Liu et al.
ONCOLOGY LETTERS (2016)
Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy
Tanner M. Johanns et al.
CANCER DISCOVERY (2016)
Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas
Jing Zeng et al.
ONCOTARGET (2016)
Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma
Elnaz Faghfuri et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2015)
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Naiyer A. Rizvi et al.
LANCET ONCOLOGY (2015)
Structural and functional features of central nervous system lymphatic vessels
Antoine Louveau et al.
NATURE (2015)
Immunosuppressive mechanisms in glioblastoma
Edjah K. Nduom et al.
NEURO-ONCOLOGY (2015)
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer
John R. Webb et al.
CANCER IMMUNOLOGY RESEARCH (2015)
4-1 BB agonists: multi-potent potentiators of tumor immunity
Todd Bartkowiak et al.
FRONTIERS IN ONCOLOGY (2015)
Immunosuppressive mechanisms of malignant gliomas: parallels at non-CNS sites
Powell Perng et al.
FRONTIERS IN ONCOLOGY (2015)
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
Anna Sophie Berghoff et al.
NEURO-ONCOLOGY (2015)
Molecular and cellular insights into T cell exhaustion
E. John Wherry et al.
NATURE REVIEWS IMMUNOLOGY (2015)
B7-H1/PD-1 Blockade Therapy in Non-Small Cell Lung Cancer Current Status and Future Direction
Scott Gettinger et al.
CANCER JOURNAL (2014)
The PD-1/PD-Ls pathway and autoimmune diseases
Suya Dai et al.
CELLULAR IMMUNOLOGY (2014)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
Derek A. Wainwright et al.
CLINICAL CANCER RESEARCH (2014)
Immunotherapy for Primary Brain Tumors: No Longer a Matter of Privilege
Peter E. Fecci et al.
CLINICAL CANCER RESEARCH (2014)
Tim-3 on Peripheral CD4+ and CD8+ T Cells Is Involved in the Development of Glioma
Song Han et al.
DNA AND CELL BIOLOGY (2014)
Low-Dose Irradiation Programs Macrophage Differentiation to an iNOS+/M1 Phenotype that Orchestrates Effective T Cell Immunotherapy
Felix Klug et al.
CANCER CELL (2013)
The Etiology of Treatment-related Lymphopenia in Patients with Malignant Gliomas: Modeling Radiation Dose to Circulating Lymphocytes Explains Clinical Observations and Suggests Methods of Modifying the Impact of Radiation on Immune Cells
Susannah Yovino et al.
CANCER INVESTIGATION (2013)
Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas
Jing Zeng et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
Rikke B. Holmgaard et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Immune-Checkpoint Blockade and Active Immunotherapy for Glioma
Brian Ahn et al.
Cancers (2013)
A dialog between glioma and microglia that promotes tumor invasiveness through the CCL2/CCR2/interleukin-6 axis
Jing Zhang et al.
CARCINOGENESIS (2012)
Improved survival time trends for glioblastoma using the SEER 17 population-based registries
Matthew Koshy et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy
Courtney A. Crane et al.
NEURO-ONCOLOGY (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model
Wim Maes et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Different radiosensitivity of CD4(+)CD25(+) regulatory T cells and effector T cells to low dose gamma irradiation in vitro
Mengde Cao et al.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY (2011)
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Roel G. W. Verhaak et al.
CANCER CELL (2010)
The role of microglia in central nervous system immunity and glioma immunology
Isaac Yang et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2010)
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Kaori Sakuishi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Glioblastoma Cancer-Initiating Cells Inhibit T-Cell Proliferation and Effector Responses by the Signal Transducers and Activators of Transcription 3 Pathway
Jun Wei et al.
MOLECULAR CANCER THERAPEUTICS (2010)
PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions
O. Akbari et al.
MUCOSAL IMMUNOLOGY (2010)
Kynurenine is an endothelium-derived relaxing factor produced during inflammation
Yutang Wang et al.
NATURE MEDICINE (2010)
The significance of OX40 and OX40L to T-cell biology and immune disease
Michael Croft et al.
IMMUNOLOGICAL REVIEWS (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
Immune regulation and control of regulatory T cells by OX40 and 4-1BB
Takanori So et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2008)
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
Arlene H. Sharpe et al.
NATURE IMMUNOLOGY (2007)
OX40 (CD134) engagement drives differentiation of CD4+ T cells to effector cells
Cortny A. Huddleston et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2006)
GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase
DH Munn et al.
IMMUNITY (2005)
Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients
AB Heimberger et al.
CLINICAL CANCER RESEARCH (2005)
Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility
MW Pedersen et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine
MW Munks et al.
IMMUNOLOGY (2004)
Natural and induced CD4+CD25+ cells educate CD4+D25-cells to develop suppressive activity:: The role of IL-2, TGF-β, and IL-10
SG Zheng et al.
JOURNAL OF IMMUNOLOGY (2004)
Constitutive EGFR signaling confers a motile phenotype to neural stem cells
JA Boockvar et al.
MOLECULAR AND CELLULAR NEUROSCIENCE (2003)
Human CD4+CD25+ regulatory cells have marked and sustained effects on CD8+ T cell activation
NOS Câmara et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
Human CD4+CD25+ regulatory, contact-dependent T cells induce interleukin 1-producing, contact-independent type 1-like regulatory T cells
D Dieckmann et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Cutting edge:: Control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells
CA Piccirillo et al.
JOURNAL OF IMMUNOLOGY (2001)
Share Paper
